Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer

Zhaoyi Feng; Wandong Xu; Chenguang Zhang; Mengran Liu; Hongwu Wen

doi:10.18632/oncotarget.14152

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer

Zhaoyi Feng _, Wandong Xu, Chenguang Zhang, Mengran Liu and Hongwu Wen

PDF | HTML | How to cite

Oncotarget. 2017; 8:8215-8225. https://doi.org/10.18632/oncotarget.14152

Metrics: PDF 1896 views | HTML 2790 views | ?

Abstract

Zhaoyi Feng1,2,*, Wandong Xu1,*, Chenguang Zhang3, Mengran Liu1, Hongwu Wen1

1Department of Obstetrics and Gynecology, Peking University First Hospital, Beijing 100034, China

2Center for Cancer Immunology and Cutaneous Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA

3Department of Medical Genetics, Capital Medical University, Beijing 100069, China

*Co-first author

Correspondence to:

Hongwu Wen, email: [email protected]

Keywords: epithelial ovarian carcinoma, Notch, Jagged1, NICD, γ-secretase

Received: July 22, 2016 Accepted: November 07, 2016 Published: December 24, 2016

ABSTRACT

Epithelial ovarian cancer (EOC) is the leading cause of death for gynecological cancer. Most patients are not diagnosed until the cancer is at an advanced stage with poor prognosis. Notch1 signaling pathway plays an oncogenic role in EOC. There have been few studies on enzymatic activity of γ-secretase and the mechanism of how γ-secretase inhibitor works on cancer cell. Here, we show that Jagged1 and NICD were highly expressed in ovarian carcinoma. The expressions of Notch1, Jagged1 and NICD in Notch1 pathway did not correlate with outcome in ovarian cancer. The enzymatic activity of γ-secretase in ovarian cancer cell lines SKOV3, CAOV3 and ES2 is significantly higher than in normal ovarian epithelial cell line T29. DAPT (a γ-secretase inhibitor) reduced the enzymatic activity of γ-secretase, inhibited the proliferation, and increased the apoptosis in ovarian cancer cell lines. Hence, γ-secretase inhibitor may become a highly promising novel therapeutic strategy against ovarian cancer in the field of precision medicine.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14152

Publication Alerts

Research Papers:

Inhibition of gamma-secretase in Notch1 signaling pathway as a novel treatment for ovarian cancer

Abstract